CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0826 (clinicaltrials.gov NCT No: NCT00411632)
Title:A Phase II Study of Erlotinib (Tarceva®) in Combination with Bexarotene (Targretin®) in Chemorefractory Patients with Advanced Non-small Cell Lung Cancer
Principal Investigator:William N. William Jr.
Treatment Agent:Bexarotene; Erlotinib
Study Status:Closed
Study Description:The goal of this clinical research study is to evaluate the effectiveness of
Tarceva® (OSI-774, erlotinib hydrochloride) in combination with Targretin®
(bexarotene) in treating NSCLC. The safety of this treatment will also be
studied, as well as the treatment's effect on different cells in the body and
the participants' overall response.

Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase II
Treatment Agents:Bexarotene
Erlotinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients will return to the clinic every 4 weeks.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:William N. William Jr.
Dept:Thoracic and Head and Neck Med
For Clinical Trial Enrollment:713-792-6363
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults